Page 5 - சுகாதாரம் சங்கம் ஆஃப் தி பிலிப்பைன்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Patient safety is at the heart of COVID‑19 vaccine development
bworldonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bworldonline.com Daily Mail and Mail on Sunday newspapers.
Multi-stakeholder call to implement UHC Law
bworldonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bworldonline.com Daily Mail and Mail on Sunday newspapers.
March 10, 2021 | 7:28 pm Font Size
AAA
DRUGMAKERS said further price controls on their products will hinder the industry in recovering from the economic downturn triggered by the pandemic.
Responding Wednesday to a legislative proposal to establish a price board for drugs, Pharmaceutical and Healthcare Association of the Philippines (PHAP) Trustee Jannette Alcantara Jakosalem said price controls will be an added burden to the industry on top of the difficult economic environment.
“Like many industries, the pharmaceutical industry has not recovered from the pandemic. The contraction of the market reached up to minus 18% in 2020. This is evidence of our struggles. On top of our struggles, the government imposed mandatory price reductions of up to 50% for 133 pharmaceutical products,” she said at a hearing of the House Committee on Trade and Industry.
PHILIPPINE STAR/MICHAEL VARCAS
As part of a science-driven industry, the biopharmaceutical industry is leading the way in developing treatments, vaccines, and diagnostics for coronavirus disease 2019 (COVID-19). Our scientists are searching for potentially useful assets that can help with the development of new or repurposed treatments or vaccines to fight against the novel coronavirus. We are leveraging our manufacturing technologies to allow the rapid upscaling of production once a medicine or vaccine candidate is identified to meet the needs of the most affected populations. Phase 3 clinical trials are being conducted to establish safety and efficacy. We are collaborating with governments, global health and research organizations, and pharmaceutical laboratories to share knowledge, libraries, and technologies.
By Teodoro B. Padilla
With more patients in need of help to access treatments, advocates welcome the recent announcement of the Department of Health (DoH) that it would allocate at least a P700-million annual budget to the cancer assistance fund. During the “Cancer Conversations: From Policy to Meaningful Action” webinar held in partnership with the
BusinessWorld, Health Secretary Francisco T. Duque III reaffirmed the government’s commitment to implement the National Integrated Cancer Control Act (NICCA).
“Historically, the budget trend for the cancer control program has been fluctuating and frankly, insufficient. By having NICCA in place and indicated in the draft Administrative Order on Cancer Assistance Fund, the annual budget for the Cancer Supportive Care and Palliative Care Medicines Access Program will now be at least 700 million pesos. This will allow us to cover more priority cancer types and allow us to give larger numbers of patients in minimizing, if no
vimarsana © 2020. All Rights Reserved.